Chemical kinetics for drug discovery to combat protein aggregation diseases

Highlights • Protein misfolding diseases largely lack effective pharmaceutical treatments. • Compounds with the ability to interfere with protein aggregation are attractive drug candidates. • The search for inhibitors requires a detailed understanding of the inhibition mechanisms. • Chemical kinetic...

Full description

Saved in:
Bibliographic Details
Published in:Trends in pharmacological sciences (Regular ed.) 2014-03, Vol.35 (3), p.127-135
Main Authors: Arosio, Paolo, Vendruscolo, Michele, Dobson, Christopher M, Knowles, Tuomas P.J
Format: Article
Language:English
Subjects:
Advanced Basic Science
aggregation kinetics
Drug Discovery
Humans
inhibition mechanism
Kinetics
Models, Molecular
neurodegenerative diseases
Neurodegenerative Diseases - drug therapy
Neurodegenerative Diseases - metabolism
Protein Folding - drug effects
Proteins - antagonists & inhibitors
Proteins - chemistry
Proteins - metabolism
Proteostasis Deficiencies - drug therapy
Proteostasis Deficiencies - metabolism
therapeutics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Protein misfolding diseases largely lack effective pharmaceutical treatments. • Compounds with the ability to interfere with protein aggregation are attractive drug candidates. • The search for inhibitors requires a detailed understanding of the inhibition mechanisms. • Chemical kinetic analysis plays a key role in identifying the inhibition mechanisms.
ISSN:0165-6147
1873-3735
DOI:10.1016/j.tips.2013.12.005